Key result
Glimepiride use was associated with lower all-cause mortality (HR 0.47; 95% CI 0.35-0.63; P<0.001) and cardiovascular mortality in patients with type 2 diabetes and chronic heart failure.
Why the study?
Glimepiride has good cardiovascular safety, but whether it benefits clinical cardiovascular outcomes remains unclear.
Does glimepiride reduce mortality and cardiovascular events in patients with type 2 diabetes and chronic heart failure?
Population
21,451 inpatients with type 2 diabetes and chronic heart failure (509 propensity score-matched pairs)
Comparison
Glimepiride treatment vs non-glimepiride
Design
Prospective cohort study
Authors
Loading...
May support glimepiride in T2D with HF; leaves open causal mortality benefit pending RCTs.
Cohort (n=21,451)
Does glimepiride reduce mortality and cardiovascular events in patients with type 2 diabetes and chronic heart failure?
Hazard Ratio: 0.47 (95% CI 0.35–0.63)
p-value: p=< 0.001
In patients with type 2 diabetes and chronic heart failure, glimepiride use was associated with significantly reduced mortality and cardiovascular events.
He et al. (2022) conducted a cohort in Type 2 diabetes and chronic heart failure (n=21,451). Glimepiride vs. No glimepiride was evaluated on All-cause mortality (HR 0.47, 95% CI 0.35-0.63, p=< 0.001). Glimepiride use was associated with lower all-cause mortality (HR 0.47; 95% CI 0.35-0.63; P<0.001) and cardiovascular mortality in patients with type 2 diabetes and chronic heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: